Anzeige
Mehr »
Samstag, 04.10.2025 - Börsentäglich über 12.000 News
Golden Cross macht sich bereit: 1.350 Goldabbaustellen, 55 Ladder-Ziele und ein historischer Volltreffer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A403UF | ISIN: SE0022049920 | Ticker-Symbol: LS60
Frankfurt
03.10.25 | 08:06
0,707 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CLINICAL LASERTHERMIA SYSTEMS AB Chart 1 Jahr
5-Tage-Chart
CLINICAL LASERTHERMIA SYSTEMS AB 5-Tage-Chart
GlobeNewswire (Europe)
551 Leser
Artikel bewerten:
(2)

Clinical Laserthermia Systems AB: CLS Recaps 2024 and Provides Outlook for 2025-26

Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that, in its recap of 2024, in the first nine months of 2024 compared to the same period 2023, CLS saw a 274% rise in net sales and a 18% reduction in operating expenses. The company shifted to a commercial partnership model and strengthened its focus on neurosurgery. With expanded market access and improved operational efficiency, CLS positions itself for continued growth, and a positive cashflow in 2026.

CLS 2024 Recap

Strong Focus on Financial Performance

Net sales for the first nine months of 2024 increased to SEK 14.2 million, compared to SEK 3.8 million in the same period of 2023. This growth was fueled by increased adoption of the ClearPoint Prism system and rising demand for sterile disposable products. In the same period, CLS operating expenses decreased by 18% as a result of the company's cost-cutting activities.

Strategic Partnerships and Neurosurgery in Focus

In October we made the pivotal decision to grow all our business through strategic partnerships, with a strengthened focus on our ongoing successful neurosurgery business with Clearpoint Neuro Inc.

Our partnership has been instrumental in driving adoption of the ClearPoint Prism® products and we have significantly expanded installations across the U.S, providing an increasing number of patients access to minimally invasive neuro-LITT treatments of the brain.

Strategic collaborations in Urology

Early in the year CLS APAC Pte Ltd received market approval for our TRANBERG® Thermal Therapy System in Singapore. In line with CLS strategic shift, we concentrated our international presence in urology to entered strategic commercial partnerships in Singapore, France and Italy, and to our study clinics in Magdeburg and Toronto where we expect initial supportive study results in 2025.

Strengthening of Technological Leadership

CLS continues to strengthen its IP portfolio. In January, we secured full rights to our MRI-based temperature measurement and laser ablation technology through an agreement with Image Guided Therapy SA. At the end of the year CLS had a total of 5 patent families with 64 patents issued.

CLS 2025-26 Outlook

Continued Revenue Growth

Looking ahead, CLS is targeting a high-end double-digit growth in revenues each year in 2025 and 2026, a growth driven largely by an expansion of the ClearPoint Prism portfolio in the U.S, increasing the addressable market by over 40%.

Streamlining Operations and Increasing Margins

We are focused on operational efficiency, aiming to reduce operating expenses by at least 30% in 2025 compared to 2024. These measures, combined with increasing scalability, are expected to drive our gross margin to 60% by the end of 2026, positioning CLS for positive cash flow by Q4 2026.

Pioneering Innovation and Partnerships

Our continued collaboration with Clearpoint Neuro, Inc. and our strategic focus on neurosurgery, reinforce our leadership in this field. By expanding our commercial partnership model across therapy-enabling organizations in market segments outside of neurosurgery, such as urology, we build on experiences gained, ensuring a broader market reach for our technology with a cost-effective commercial set-up.

A Bright Future

The next two years mark a pivotal phase for CLS. By aligning our resources with our new strategic priorities, together with our partners, we are building a strong foundation for profitability and sustainable growth. Our joint focus on meeting customer expectations, operational excellence, and market expansion ensures we remain at the forefront of delivering transformative therapeutic solutions.

Thank you for your trust and support. Together, we are driving CLS toward a future of sustained success and value creation.

Dan J. Mogren
CEO, Clinical Laserthermia Systems AB

For more information, please contact
Dan J Mogren, CEO Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com


About CLS
Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG®|Thermal Therapy System and ClearPoint Prism Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se


© 2025 GlobeNewswire (Europe)
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.